3.8 Review

Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia

Journal

FUTURE CARDIOLOGY
Volume 1, Issue 1, Pages 39-59

Publisher

FUTURE MEDICINE LTD
DOI: 10.1517/14796678.1.1.39

Keywords

adipose autodysharmonia; adiposopathy diabetes; Food and Drug Administration; hypertension; obesity metabolic cycle; metabolic syndrome; obesity; regulatory

Funding

  1. Alteon
  2. Aventis
  3. Bayer
  4. Boehringer Ingelheim
  5. Boehringer Mannheim
  6. Bristol-Myers Squibb
  7. Fujisawa
  8. Ciba-Geigy
  9. GelTex
  10. Glaxo
  11. Genetech
  12. Hoechst Roussel
  13. KOS
  14. Lederle
  15. Marion Merrell Dow
  16. Merck
  17. Merck Schering-Plough
  18. Miles
  19. Novartis
  20. Parke-Davis
  21. Pfizer
  22. Purdue
  23. Reliant
  24. Roche
  25. Rorer
  26. Regeneron
  27. Sandoz
  28. Sankyo
  29. Sanofi
  30. Shering Plough
  31. Searle
  32. SmithKline Beacham
  33. Takeda
  34. TAP
  35. UpJohn
  36. Upsher Smith
  37. Warner-Lambert
  38. Wyeth-Ayerst
  39. AstraZenca
  40. NIH [K23-RR16075]
  41. NIH/DHS/DHHS [MO1-RR-00633]
  42. CDC [H75/CCH523202]
  43. AHA [0465017Y]

Ask authors/readers for more resources

Adiposopathy is defined as pathological adipose tissue function that may be promoted and exacerbated by fat accumulation (adiposity) and sedentary lifestyle in genetically susceptible patients. Adiposopathy is a root cause of some of the most common metabolic diseases observed in clinical practice, including Type 2 diabetes mellitus, hypertension and dyslipidemia. The most common term for the metabolic consequences of adiposopathy is currently 'the metabolic syndrome'. Drug usage to treat the metabolic syndrome has focused on the safety and efficacy of treatments directed towards individual components of the metabolic syndrome, and not so much upon adiposopathy itself. However, enough is known about the pathophysiology of adiposopathy to propose diagnostic criteria. Regulatory issues are important obstacles to the research and development of new drug treatments for the metabolic syndrome. It is hoped that these obstacles can, to some extent, be addressed and overcome by clearly defining and increasing our understanding of adiposopathy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available